Skip to main content

Table 5 G2 at week 6, 7 and 2 weeks after RT in BC and HNC patients

From: A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients

Visit Statistics BC HNC
SOC Xonrid® + SOC SOC Xonrid® + SOC
WEEK 6 NO G2 3 (16.7%) 7 (38.9%) 6 (37.5%) 9 (45.0%)
G2+ 15 (83.3%) 11 (61.1%) 10 (62.5%) 11 (55.0%)
p-value (Chi-square)   0.1   0.6
Logistic regression Odds ratio   0.31   0.73
95% CI   0.07–1.50   0.19–2.81
p-value   0.1   0.6
WEEK 7 NO G2    3 (21.4%) 5 (25.0%)
G2+    11 (78.6%) 15 (75.0%)
p-value (Chi-square)     0.8
Logistic regression Odds ratio     0.82
95% CI     0.16–4.17
p-value     0.8
2 WEEKS AFTER END OF TREATMENT NO G2 3 (16.7%) 6 (35.3%) 12 (100.0%) 15 (100.0%)
G2+ 15 (83.3%) 11 (64.7%)   
p-value (Chi-square)   0.2   
Logistic regression Odds ratio   0.37   
95% CI   0.07–1.80   
p-value   0.2